key: cord-0805903-xpf0f68c authors: Abdelrahman, Zeinab; Chen, Zuobing; Lyu, Haoyu; Wang, Xiaosheng title: Comparisons of the immunological landscape between COVID-19, influenza, and respiratory syncytial virus patients by clustering analysis date: 2021-04-23 journal: Comput Struct Biotechnol J DOI: 10.1016/j.csbj.2021.04.043 sha: 028ea88c648a83e8e4f1e3c473454401eed5a6b6 doc_id: 805903 cord_uid: xpf0f68c BACKGROUND: COVID-19 has stronger infectivity and a higher risk for severity than most other contagious respiratory illnesses. The mechanisms underlying this difference remain unclear. METHODS: We compared the immunological landscape between COVID-19 and two other contagious respiratory illnesses (influenza and respiratory syncytial virus (RSV)) by clustering analysis of the three diseases based on 27 immune signatures’ scores. RESULTS: We identified three immune subtypes: Immunity-H, Immunity-M, and Immunity-L, which displayed high, medium, and low immune signatures, respectively. We found 20%, 35.5%, and 44.5% of COVID-19 cases included in Immunity-H, Immunity-M, and Immunity-L, respectively; all influenza cases were included in Immunity-H; 66.7% and 33.3% of RSV cases belonged to Immunity-H and Immunity-L, respectively. These data indicate that most COVID-19 patients have weaker immune signatures than influenza and RSV patients, as evidenced by 22 of the 27 immune signatures having lower enrichment scores in COVID-19 than in influenza and/or RSV. The Immunity-M COVID-19 patients had the highest expression levels of ACE2 and IL-6 and lowest viral loads and were the youngest. In contrast, the Immunity-H COVID-19 patients had the lowest expression levels of ACE2 and IL-6 and highest viral loads and were the oldest. Most immune signatures had lower enrichment levels in the intensive care unit (ICU) than in non-ICU patients. Gene ontology analysis showed that the innate and adaptive immune responses were significantly downregulated in COVID-19 versus healthy individuals. CONCLUSIONS: Compared to influenza and RSV, COVID-19 displayed significantly different immunological profiles. Elevated immune signatures are associated with better prognosis in COVID-19 patients. The coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported to exceed 126 million cases and resulted in more than 2.7 million deaths globally as of March 26, 2021 [1] . shares similar clinical presentations with influenza and respiratory syncytial virus (RSV), such as cough, fever, severe lung infections, and occasional respiratory failure causing deaths [2] , nevertheless, COVID-19 has also demonstrated distinct clinical characteristics, such as gastrointestinal discomfort, nerve injuries, and hypogeusia [3, 4] . Compared to other contagious respiratory illnesses, such as influenza and RSV, COVID-19 has stronger infectivity and a higher risk for severity, such as respiratory distress and systematic inflammation [3, 5] . More seriously, COVID-19 often has a long incubation period that significantly increases its transmissibility [3, 5, 6] . Unlike many other respiratory viruses, SARS-CoV-2 infection may result in host hyperinflammatory response, characterized by a high level of circulating inflammatory cytokines and interleukine-6 (IL-6) [7] . Several studies have shown that a large amount of type I interferon promoted inflammatory cytokines production and resulted in lethal pneumonia [8, 9] . Immune dysfunction is also a characteristic of COVID-19 [10] ; as shown in severe COVID-19 cases, the total numbers of T and B cells are reduced, resulting from overproduced pro-inflammatory cytokines [11] . To uncover potential mechanisms underlying the significantly different clinical characteristics of COVID-19, we compared the immunological landscape between COVID-19, influenza, and RSV based on their gene expression profiles. We performed a clustering analysis to identify immune subtypes of COVID-19, influenza, and RSV based on the enrichment levels of 27 immune signatures. We identified three immune subtypes with high, medium, and low immune signatures, respectively, and dissected these subtypes' molecular features. We also explored correlations between these immune signatures and various clinical characteristics in COVID-19 patients. This study aimed to provide new insights into the immunological landscape of COVID-19. 4 We collected eight gene expression profiling datasets, including four COVID-19 RNA-seq datasets [12] [13] [14] [15] , one RSV RNA-seq dataset from the Gene Expression Omnibus database (GEO, https://www.ncbi.nlm.nih.gov/geo/), one RSV microarray dataset [16] , one influenza microarray dataset from GEO, and one microarray dataset for both RSV and influenza [17] ( patients from Canada and the UK, respectively, and the two RSV datasets included patients from the UK and the USA. The patients' tissues in these datasets originated from the upper airway, peripheral blood mononuclear cell, leukocytes, and blood. Next, we performed quality control analysis to detect outliers in each dataset using WGCNA [18] . Finally, we merged these datasets using the "merge" function in the R package "base" and performed the adjustment of batch effects and normalization of the combined data using the "normalizeBetweenArrays" function in the R package "limma." Because this study aimed to compare immune signatures between COVID-19, influenza, and RSV, the bacterial and other anonymous viruses-associated samples were excluded. We performed an extensive literature search for immune signatures associated with respiratory viruses' infection and collected 27 immune signatures involving 136 marker genes [19] [20] [21] [22] . We first quantified the enrichment levels of the 27 immune signatures in each sample by the single-sample gene-set enrichment analysis (ssGSEA) [23] . Based on the ssGSEA scores of the 27 immune signatures, we performed hierarchical clustering of the samples in the merging dataset based on the Euclidean metrics. We identified gene ontology (GO) and KEGG pathways upregulated and downregulated in COVID-19, influenza, RSV, and their immune subtypes by GSEA [24] (R implementation) with a threshold of adjusted P value < 0.05. We used WGCNA [18] to identify gene modules significantly enriched in immune subtypes based on gene co-expression network analysis. Based on the expression correlations between the gene modules' hub genes, we identified the GO terms significantly correlated to specific traits. In the comparison of different groups of data, we used Student's t-test or ANOVA test if they were normally distributed; otherwise, we used the Mann-Whitney U test or Kruskal-Wallis test. We used the Pearson correlation coefficient (R) to evaluate the expression correlation between two genes and the Spearman correlation coefficient (ρ) to assess correlations between other variables. We adjusted P values in multiple tests using the false discovery rate (FDR), which were calculated by the Benjamini-Hochberg method. We performed all statistical analyses using R programming (version 4.0.2). Based on the 27 immune signatures' enrichment scores, we hierarchically clustered 6 the 809 virus-infected patient samples based on the Euclidean distance metric. We obtained three clear clusters, termed Immunity-H, Immunity-M, and Immunity-L, which displayed the highest, medium, and lowest immune signatures levels, respectively ( Figure 1A ). In fact, among the 27 immune signatures, 21 displayed significantly higher enrichment scores in Immunity-H than in Immunity-M and Immunity-L (one-way ANOVA test, P < 0.05) ( Figure 1B) . We found 20%, 35 Figure 1C ). Angiotensin-converting enzyme 2 (ACE2) is the host cell receptor of SARS-CoV and SARS-CoV-2 [3] . We found that ACE2 expression levels were the highest and lowest in Immunity-M and Immunity-H, respectively (two-tailed Student's t-test, P < 0.05) ( Figure 1D ). IL-6 has been indicated as an adverse prognosticator of COVID-19. Notably, the expression levels of IL-6 were the highest and lowest in Immunity-M and Immunity-H, respectively (P < 0.05) ( Figure 1D ). When the cases of influenza and RSV were excluded, the expression levels of ACE2 and IL-6 were still the highest and lowest in Immunity-M and Immunity-H, respectively (P < 0.05) ( Figure 1D ). It indicated that the COVID-19 cases in Immunity-M and Immunity-H may have different prognoses. Indeed, the COVID-19 patients were the youngest and oldest in Immunity-M and Immunity-H, respectively (Kruskal-Wallis test, P = 0.003) ( Figure 1E ). Moreover, the COVID-19 patients had the lowest and highest viral loads in Immunity-M and Immunity-H, respectively (P = 0.004) ( Figure 1F ). The expression levels of ACE2 and IL-6 were inversely correlated with viral loads in COVID-19 patients (Spearman correlation, ρ = -0.29, P < 0.001, ρ = -0.12, P < 0.015, respectively) ( Figure 1G ). Meanwhile, we observed a strong expression correlation between ACE2 and IL-6 in COVID-19 patients (Pearson correlation R = 0.65, P < 0.001) ( Figure 1H ). Overall, these results indicate that the host immune response to SARS-CoV-2 infection is likely to be more heavily dysregulated than the response to the other viruses' infection. ACE2 and TMPRSS2 are two crucial molecules for SARS-CoV-2 invading host cells [25] . We found that ACE2 expression levels were significantly higher in COVID-19 patients than in healthy controls, influenza, and RSV patients (P < 0.05) ( GO terms were enriched in RSV patients, most of which were associated with immune regulation ( Figure 2E) . Surprisingly, none of these GO terms were commonly upregulated or downregulated among the three groups of virus-infected patients, indicating unique molecular alterations in each group of virus-infected patients. 8 We also conducted a comparison of gene expression profiles between the COVID-19 patients and influenza and RSV patients. We found 126 GO terms highly enriched in COVID-19, most of which were involved in the regulation of metabolism, chemokines, and cytokines. In addition, 32 GO terms were downregulated in COVID-19, which were mainly associated with genomic stability regulation ( Figure 2F and Supplementary Figure S1A ). Besides, we compared gene expression profiles between Immunity-H, Immunity-M, and Immunity-L. We found 107 GO terms significantly upregulated in Immunity-H versus Immunity-L, and 136 GO terms significantly upregulated in Immunity-M versus Immunity-H (Supplementary Figure S1B , C, D). As expected, these GO terms were mainly involved in the regulation of the immune system. Collectively, these results indicate that the host immune response to SARS-CoV-2 is significantly different from that of the other viruses and that SARS-CoV-2 infection may affect the host metabolic process and genomic stability. We used WGCNA [18] to identify similar co-expression gene modules that We fibrinogen, hospital free days (45 days follow-up), lactate, procalcitonin, and ventilatorfree days. Both APACHE II and SOFA scores measure the severity of ICU patients [26] . The Charlson score predicts the ten-year mortality for a patient with a range of comorbid conditions [27] . The CRP, D-dimer, ferritin, fibrinogen, lactate, and procalcitonin are laboratory measurements whose high levels were correlated with the severity of COVID-19 [28] . Notably, we found that 20 immune signatures had significantly lower enrichment levels (ssGSEA scores) in ICU than in non-ICU patients (P < 0.05) ( Figure 4A ). Only two immune signatures (type II IFN reponse and inflammatory cytokines) had significantly higher ssGSEA scores in ICU than in non-ICU pateints. Moreover, most of these immune signatures' ssGSEA scores were negatively correlated with the levels of CRP, D-dimer, 10 ferritin, fibrinogen, lactate, and procalcitonin ( Figure 4B ). In constrast, a majority of these immune signatures' ssGSEA scores were positively correlated with hospital free days and ventilator-free days. Collectively, these results suggest that elevated immune signatures are likely to be associated with better prognosis in COVID-19 patients. Respiratory tract infection is liable for undue disease burden [29] . The innate and adaptive immune responses to respiratory virus infection are critical for sustaining a healthy respiratory system and preventing pulmonary disease [30] . Although COVID-19 shares certain primary symptoms with influenza and RSV [31, 32] , its transmissibility and destructivity far exceed influenza and RSV [1] . The unique host immune response in COVID-19 patients could greatly contribute to this disease's high transmissibility and destructivity [33] . For example, SARS-CoV-2 infection may not always employ interferon production but delay or suppress interferon II or III production in lung tissues [34] . Upon infection, the influenza virus is recognized by host cells through pathogenassociated molecular patterns (PAMPs) [35] . PAMPs are recognized by TLRs, RIG-I, and NLRP3 to generate pro-inflammatory cytokines and type I interferon production, which has strong antiviral activity by limiting virus replication in host cells. Type I interferons can induce STAT activation and transcription of the interferon-stimulated gene to influence innate and adaptive immune responses. Furthermore, host immune cells recruit alveolar macrophages to activate apoptotic influenza virus-infected cells, while blood-derived macrophages infected with influenza viruses produce large amounts of pro-inflammatory cytokines [35] . RSV infection elicits a strong innate immune response, especially respiratory tract neutrophil response [36] . The peak of neutrophil response often concurs with maximum clinical severity and viral load. However, because RSV infection can reduce natural killer (NK) cell count to regulate the inflammatory response, a lower NK cell count is correlated with more serious infection [37] . Upon acute infection, the adaptive immune response among RSV patients is activated via recruiting CD8 + T cells to clear viruses. Meanwhile, B cells play an important role in the production of protective antibodies. RSV infection also triggers interferon II production, which plays a strong protective role against virus infection [38] . Our results demonstrated that compared to COVID-19, influenza and RSV 11 patients elicited a stronger innate immune response, e.g., more interferons I production, macrophages, NK cells, and dendritic cells. Furthermore, influenza and RSV patients elicited a stronger adaptive immune response described by more B and T cell production. Compared to influenza and RSV, COVID-19 is likely to display lower immune signatures and higher IFN II production, leading to poor prognosis and worse outcomes. pathogens, abnormal production of this protein could be responsible for resistance to the cytotoxic activity of NK and CD8 + T cells. It has been shown that target pathogen cells could employ various escape mechanisms against perforin activity [39] . The clustering analysis showed that Immunity-M and Immunity-L harbored 80% of COVID-19 patients, suggesting that most COVID-19 patients have an inadequate immune response to virus infection. Furthermore, we found that molecular and clinical features were significantly different between COVID-19 patients in Immunity-M and Immunity-H. For example, Immunity-M patients had significantly higher expression levels of ACE2 and IL-6 while lower viral loads than Immunity-H patients. Immunity-M patients were younger than Immunity-H patients. The lower viral loads in Immunity-M than in Immunity-H patients could explain why the former had a weaker immune response than the latter. In addition, we found that the expression levels of ACE2 and IL-6 had a negative correlation with viral loads in COVID-19 patients. The negative association between ACE2 and viral loads could be attributed to that ACE2 can reduce viral loads [40] . Interestingly, younger COVID-19 patients have a lower immune response and fewer viral loads in Immunity-M than older patients in Immunity-H. A potential explanation could be that the immune system is often dysfunctional and heterogeneous in older people [41] . Through aging, the immune system often changes in two ways [41] . One is immunosenescence; that is, dysfunctional cells become epigenetically locked into a proinflammatory state, secreting cytokines and chemokines. The other one is inflamm-aging arising from the overactive and ineffective alert system [41] . In addition, when elderly alveolar TLRs detect the pathogen, they respond by producing type I interferons to attract immune cells to the site of infection. Furthermore, although the number of macrophages increases with age, their plasticity to convert between pro-and anti-inflammatory states is reduced [34] . Therefore, the higher immune signatures in Immunity-H are likely to be associated with dysfunctional immune responses in older COVID-19 patients, leading to worse clinical outcomes, as observed in the previous results. Besides, we found that IFITM3, a gene playing a critical role in promoting the immune system's defense against viruses, was significantly downregulated in COVID-19 versus influenza and RSV patients. Again, it suggests an inadequate immune response in COVID-19 versus influenza and RSV patients, although the levels of pro-inflammatory cytokines are remarkably higher in COVID-19 than in influenza and RSV patients. In addition to the pathways of immune responses, several metabolic pathways were dysregulated in COVID-19 patients. These metabolic pathways are involved in the abnormal activity of mitochondrial respiratory chain, negative regulation of signaling receptor activity, dysregulation of extracellular matrix binding, dysregulation of nucleoside phosphate catabolic process, regulation of cytokinesis and chemotaxis, regulation of TOR signaling, and decreased pulmonary function. These data may explain why many COVID-19 patients exhibited severe cardiovascular and pulmonary injury [42] . Moreover, the extracellular matrix regulation is enriched in several COVID-19 patients, which plays a vital role in establishing and maintaining immune homeostasis [43] . Also, we found a strong correlation between metabolic dysregulation and immunogenesis in COVID-19 patients. Our results also showed that some COVID-19 patients had a stronger immune response than other COVID-19 patients, while these patients often had more severe clinical outcomes. The main reason could be that their hyperinflammatory reaction to SARS-CoV-2 infection, known as cytokine storm [44] [45] , resulted in serious organ damage. Besides, our results showed that ACE2 expression levels were significantly lower in immunity-H than in immunity-M and immunity-L. It indicates that ACE2 upregulation could lead to antiviral immunosuppression to cause a worse prognosis in COVID-19 patients [46, 47] . Although our study provides a strong base for further investigation into different Ethical approval and consent to participate were waived since we used only publicly available data and materials in this study. Not applicable. The authors declare that they have no competing interests. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses Brachial Plexus Neuropathies During the COVID-19 Pandemic: A Retrospective Case Series of 15 Patients in Critical Care COVID-19 versus the 1918 influenza pandemic: different virus, different age mortality patterns Identifying novel factors associated with COVID-19 transmission and fatality using the machine learning approach WGCNA: an R package for weighted correlation network analysis COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans Upper airway gene expression differentiates COVID-19 from other acute respiratory illnesses and reveals suppression of innate immune responses by SARS-CoV-2 Large-Scale Multi-omic Analysis of COVID-19 Severity A Transcriptome Fingerprinting Assay for Clinical Immune Monitoring Transcriptomic profiling in childhood H1N1/09 influenza reveals reduced expression of protein synthesis genes WGCNA: an R package for weighted correlation network analysis COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses A dynamic COVID-19 immune signature includes associations with poor prognosis COVID-19 and flu: conserved or specific immune signature? Classification of triple-negative breast cancers based on Immunogenomic profiling GSVA: gene set variation analysis for microarray and RNA-seq data GSEA-P: a desktop application for Gene Set Enrichment Analysis SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor APACHE II: a severity of disease classification system A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Hematological findings and complications of COVID-19 Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis The host immune response in respiratory virus infection: balancing virus clearance and immunopathology Co-infection with SARS-CoV-2 and influenza A virus Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function Immune responses to influenza virus infection A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses The Human Immune Response to Respiratory Syncytial Virus Infection Perforin: an important player in immune response Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 Why does COVID-19 disproportionately 19 affect older people Immune and Metabolic Signatures of COVID-19 Revealed by Transcriptomics Data Reuse Coronavirus infections and immune responses Immune dysfunction following COVID-19, especially in severe patients Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell Not available.